Comparative effect of two methods of relaxation and meditation on serum levels of IL-2, TNF-a, IL-17A and IL-23 cytokines

Comparison of the effects of relaxation and meditation techniques on serum levels of IL-2, TNF-a, IL-17A and Il-23 in the patients with coronary artery disease who refer to the outpatient heart clinic in 2018

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150519022320N16

Enrollment

120

Registered

2019-01-05

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease. Chronic ischemic heart disease

Interventions

Intervention 1: Intervention group 1: A relaxation program will be planned and implemented in seven stages for the relaxation group, the steps of which will be:1. Identify the muscles and muscle group

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Known coronary artery disease (based on medical records); History of admission in section CCU Expression of willingness to participate in the study

Exclusion criteria

Exclusion criteria: History of heart failure History of mental illness or use of psychoactive drugs, The history of autoimmune diseases, allergies and immune-related diseases

Design outcomes

Primary

Measure	Time frame
Measuring the serum level of IL-17A. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of IL-23. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of IL-2. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of TNF-a. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.	—

Measure

Time frame

Measuring the serum level of IL-17A. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of IL-23. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of IL-2. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.;Measuring the serum level of TNF-a. Timepoint: Before the start of the study and three months after the start of the study. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayebeh Mirzaei

Rafsanjan University of Medical Sciences

t.mirzaei@rums.ac.ir+98 34 3425 5900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026